Detailed Information

Cited 9 time in webofscience Cited 9 time in scopus
Metadata Downloads

A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma

Authors
Sym, Sun JinLee, Dae HoKang, Hye JinNam, Seung HyunKim, Ho YoungKim, Seok JinEom, Hyeon SeokKim, Won SeogSuh, Cheolwon
Issue Date
Jun-2009
Publisher
SPRINGER
Keywords
Oxaliplatin; Lymphoma; Salvage therapy; Chemotherapy
Citation
CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.64, no.1, pp 27 - 33
Pages
7
Indexed
SCIE
SCOPUS
Journal Title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume
64
Number
1
Start Page
27
End Page
33
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/35576
DOI
10.1007/s00280-008-0847-y
ISSN
0344-5704
1432-0843
Abstract
We investigated the efficacy and toxicity of the etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx), in which oxaliplatin (Ox) was substituted for cisplatin in the ESHAP [etoposide (E), methylprednisolone (S), high-dose cytarabine (HA), and cisplatin (P)] regimen, for patients with refractory/relapsed aggressive non-Hodgkin's lymphoma (NHL). The ESHAOx consisted of E (40 mg/m(2) on days 1-4), S (500 mg on days 1-5), HA (2 g/m(2) on day 5), and Ox (130 mg/m(2) on day 1) every 3 weeks to a maximum of six cycles. Responses were assessed every three cycles. Twenty-seven patients were enrolled (19 with relapsed and 8 with refractory; 10 with an IPI score of 3-5). The overall response rate was 63% [95% confidence interval (95% CI) 45-81%], including eight complete remissions (CR) and one unconfirmed CR (33%). The median duration of response was 9.9 months (95% CI 5.7-14.2 months). After a median follow-up of 18.6 months, the median progression-free and overall survival was 5.3 months (95% CI 3.9-6.7 months) and 15.1 months (95% CI 9.4-20.9 months), respectively, with a 1-year survival rate of 61.5%. Most common grade 3/4 hematologic toxicities were neutropenia (56%) and thrombocytopenia (35%), whereas no patient experienced grade 3/4 renal or neurotoxicity. The efficacy and toxicity profiles suggested that the ESHAOx can be an alternative option for patients with refractory/relapsed aggressive NHL.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE